Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation.
We previously reported clinical improvement, increase in putamen [(18)F]-dopa uptake on PET imaging, and neuropathologic evidence of sprouting of dopaminergic fibers following chronic intraputaminal delivery of glial cell line-derived neurotrophic factor (GDNF) in idiopathic Parkinson disease (PD).(1-3) We now provide clinical and PET evidence of persistent efficacy lasting for at least 3 years following cessation of GDNF infusion in a patient with PD. This is a single-case observational study, providing Class IV evidence.
From the Institute of Clinical Neurosciences (N.K.P., S.J., S.S.G.), Frenchay Hospital, Bristol; and Imperial College London (N.P., G.R.H., D.J.B.), Division of Brain Sciences, Hammersmith Hospital, London, UK.
Nikunj K
NK
Patel
Nicola
N
Pavese
Shazia
S
Javed
Gary R
GR
Hotton
David J
DJ
Brooks
Steven S
SS
Gill
D000978:Antiparkinson Agents / Q000008:administration & dosage*; D019788:Fluorodeoxyglucose F18; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011699:Putamen / Q000187:drug effects* / Q000502:physiology*; D012720:Severity of Illness Index; D013997:Time Factors; D014055:Tomography, Emission-Computed
D000978:Antiparkinson Agents; D051100:Glial Cell Line-Derived Neurotrophic Factor; D019788:Fluorodeoxyglucose F18